StartupLanes

I am a founder & technologist with 14+ years of post-PhD experience in semiconductor devices, nanoelectronics and wearables. As Cofounder & CTO of HemodynamiQ, I lead the development of a patent-pending wearable device that addresses one of cardiology's most pressing challenges: preventing the 43% of heart failure readmissions driven by undetectable hemodynamic deterioration.

THE CLINICAL PROBLEM WE'RE SOLVING

The AHA's October 2023 CKM Syndrome framework reveals a fundamental truth: 38 million Stage 3-4 CKM patients drive HF readmissions through two interconnected pathological mechanisms. Kidney disease causes progressive fluid retention and sodium overload (manifesting as fluid volume overload, elevated JVP, and LV pressure). Concurrently, metabolic dysfunction impairs autonomic nervous system function while directly stiffening the left ventricle, further elevating LV pressure.

These hemodynamic markers precede clinical decompensation by 2-4 weeks—yet remain invisible to current monitoring approaches because:

a) Incumbent solutions serve only the sickest 5-10% of heart failure patients
b) Primary care monitoring relies on clinical assessment and BNP markers—insufficient for early intervention

This surveillance gap results in preventable readmissions costing $40+ B annually and perpetuates cycles of acute decompensation for millions.

OUR TECHNOLOGY SOLUTION

HemodynamiQ's patent-pending multi-sensor based hemodynamics monitoring platform represents a fundamental shift in wearable cardiac monitoring. Our non-invasive patch simultaneously measures three distinct congestion phenotypes.

Why now?

The 24-month window (2025-2027) represents a unique early-adoption sweet spot: high physician awareness of CKM Syndrome framework, zero market saturation for wearable solutions in this segment, and payer momentum toward preventive cardiac monitoring reimbursement.

OUR MISSION

Make continuous cardiac hemodynamic monitoring universally accessible, enabling primary care teams to prevent heart failure progression before patients reach critical illness—transforming cardiac care from reactive crisis management to proactive hemodynamic surveillance.

LET'S CONNECT

If you're interested in:

a) Joining HemodynamiQ as investor, partner, or strategic advisor
b) Deploying our pilot program at your health system
c) Discussing licensing or co-development opportunities
d) Sharing insights on CKM Syndrome and preventive cardiac care